Somatic cell therapy is the only feasible option, and clinical trials have already started mostly for the treatment of cancer and blood disorders. This approach is divided into two groups on the basis of the end result of the process:
(i) addition or augmentation gene therapy and
(ii) targetted gene transfer.



